why choose us

First received: January 24, 2023

Clinical Trial: Testing the Use of BRAF-Targeted Therapy After Surgery and Usual Chemotherapy for BRAF-Mutated Colon Cancer

Study Status: Completed

Recruit Status: RECRUITING

Condition: Colon Adenocarcinoma

Study Type: INTERVENTIONAL


Official Title: Randomized Trial of Consolidation Targeted Adjuvant Therapy With Encorafenib and Cetuximab Versus Usual Care for Patients With Stage II/III BRAF V600E Colon Cancer

Brief Summary: This phase II/III trial compares treatment with encorafenib and cetuximab to usual care (patient observation) for reducing the chance of cancer recurrence after standard surgery and chemotherapy in patients with BRAF-mutated stage IIB-III colon cancer.Encorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.Cetuximab is in a class of medications called monoclonal antibodies.It binds to a protein called EGFR, which is found on some types of tumor cells.This may help…

Read more